Genenta Sciences (GNTA) Investment Analysis: ‘Temferon’ long-term survival signal & mRCC combo Phase 1/2a underway — €20M mandatory convertible bond extends runway
Genenta Sciences (GNTA) Investment Analysis: ‘Temferon’ long-term survival signal & mRCC combo Phase 1/2a underway — €20M mandatory convertible bond extends runway※ Genenta Sciences (Nasdaq: GNTA) is advancing its autologous hematopoietic stem-cell gene therapy ‘Temferon’. In GBM Phase 1/2a long-term follow-up, it reported a 2-year OS of 29% and median OS of 17 months. A Phase 1/2a in metastatic..
Quoin Pharmaceuticals (ADR, QNRX) Stock Price Analysis: First Therapy Shot for Netherton Syndrome — QRX003 Gains RPDD and Accelerates Pivotal Trials
Quoin Pharmaceuticals (ADR, QNRX) Stock Price Analysis: First Therapy Shot for Netherton Syndrome — QRX003 Gains RPDD and Accelerates Pivotal Trials※ Quoin Pharmaceuticals (ADR: QNRX) is a rare/orphan-disease-focused biotech developing QRX003 (once-daily topical lotion) as its pivotal asset for Netherton syndrome (NS). In June 2025, the FDA granted Rare Pediatric Disease Designation (RPDD) to QR..